The Contribution of Abdominal Obesity and Dyslipidemia to Metabolic Syndrome in Psychiatric Patients
2
조회
0
다운로드
1
인용
0
참고문헌
초록
Background/Aims: Metabolic syndrome is an emerging risk factor for cardiovascular disease. This study investigated the prevalence of metabolic syndrome among psychiatric patients in order to identify the dominant factors of metabolic syndrome. Methods: We enrolled 225 patients who had been admitted to a chronic psychiatric hospital from October 2005to February 2006. The prevalence of metabolic syndrome was assessed based on the Adult Treatment Panel (ATP)-III with the new criterion of waist circumference in the Asia-Pacific Region. Results: The study population was relatively young (41.1 ± 8.8 years) and obese (waist in men, 91.3 ± 9.2 cm;waist in women, 84.1 ± 8.8 cm). Sixty percent of patients met the waist criterion of metabolic syndrome and 56%met the low high density lipoprotein (HDL) criterion. The mean serum triglycerides were high (170.0 ± 119.7 mg/dL)and 46% of patients met the triglyceride criterion. In contrast, less than 10% of patients showed impaired fasting glucose or high blood pressure (5%, 9%, respectively). The overall prevalence of metabolic syndrome was 34.2% by applying ATP-III criteria (40% in men and 20% in women, respectively). No specific anti-psychotic drugs were related to significant increase in the incidence of metabolic syndrome. Conclusions: Abdominal obesity and dyslipidemia (low HDL and high triglycerides) were dominant contributing factors of metabolic syndrome among psychiatric patients, and the affected age groups were relatively young. These findings indicate that active and early screening, including triglycerides, HDL, and waist measurement, are absolutely essential to managing metabolic syndrome in psychiatric patients. (Korean J Intern Med 2010;25:168-173)
Abstract
Background/Aims: Metabolic syndrome is an emerging risk factor for cardiovascular disease. This study investigated the prevalence of metabolic syndrome among psychiatric patients in order to identify the dominant factors of metabolic syndrome. Methods: We enrolled 225 patients who had been admitted to a chronic psychiatric hospital from October 2005to February 2006. The prevalence of metabolic syndrome was assessed based on the Adult Treatment Panel (ATP)-III with the new criterion of waist circumference in the Asia-Pacific Region. Results: The study population was relatively young (41.1 ± 8.8 years) and obese (waist in men, 91.3 ± 9.2 cm;waist in women, 84.1 ± 8.8 cm). Sixty percent of patients met the waist criterion of metabolic syndrome and 56%met the low high density lipoprotein (HDL) criterion. The mean serum triglycerides were high (170.0 ± 119.7 mg/dL)and 46% of patients met the triglyceride criterion. In contrast, less than 10% of patients showed impaired fasting glucose or high blood pressure (5%, 9%, respectively). The overall prevalence of metabolic syndrome was 34.2% by applying ATP-III criteria (40% in men and 20% in women, respectively). No specific anti-psychotic drugs were related to significant increase in the incidence of metabolic syndrome. Conclusions: Abdominal obesity and dyslipidemia (low HDL and high triglycerides) were dominant contributing factors of metabolic syndrome among psychiatric patients, and the affected age groups were relatively young. These findings indicate that active and early screening, including triglycerides, HDL, and waist measurement, are absolutely essential to managing metabolic syndrome in psychiatric patients. (Korean J Intern Med 2010;25:168-173)
참고문헌 (14)
- Reaven GM, "Banting lecture 1988. Role of insulin resistance in human disease", Diabetes, 37, pp.1595~1607 (1988)
- Allebeck P, "Schizophrenia: a life-shortening disease", Schizophr Bull, 15, pp.81~89 (1989)
- Osby U, "Mortality and causes of death in schizophrenia in Stockholm county, Sweden", Schizophr Res, 45, pp.21~28 (2000)
- Meyer JM, "Effects of atypical antipsychotics on weight and serum lipid levels", J Clin Psychiatry, 62(27), pp.27~34 (2001)
- Shirzadi AA, "Side effects of atypical antipsychotics: extrapyramidal symptoms and the metabolic syndrome", Harv Rev Psychiatry, 14, pp.152~164 (2006)
- Wu RR, "Effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia", Psychopharmacology (Berl), 186, pp.572~578 (2006)
- Basu R, "The prevalence of the metabolic syndrome in patients with schizoaffective disorder: bipolar subtype", Bipolar Disord, 6, pp.314~318 (2004)
- Cohn T, "Characterizing coronary heart disease risk in chronic schizophrenia: high prevalence of the metabolic syndrome", Can J Psychiatry, 49, pp.753~760 (2004)
- De Hert MA, "Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication", Schizophr Res, 83, pp.87~93 (2006)
- Heiskanen T, "Metabolic syndrome in patients with schizophrenia", J Clin Psychiatry, 64, pp.575~579 (2003)
- McEvoy JP, "Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III", Schizophr Res, 80, pp.19~32 (2005)
- Inoue S, "The Asia-Pacifia perspective: redefining obesity and its treatment. Crows Nest: Health Communications Australia Pty Limited on behalf of the Steering Committee", ~ (2000)
- 최성희, "The Prevalence of the Metabolic Syndrome in Korean Adults: Comparison of WHO and NCEP Criteria", Yonsei Medical Journal, 46(2), pp.198~205 (2005), 연세대학교의과대학
- Saito I, "Prevalence of metabolic syndrome in young men in Japan", J Atheroscler Thromb, 14, pp.27~30 (2007)